Your browser doesn't support javascript.
loading
Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders.
Calcagno, Andrea; Dal Conte, Ivano; Cattaneo, Dario; Testi, Roberto; Mistrangelo, Massimiliano; Gervasoni, Cristina; de Nicolò, Amedeo; Bonora, Stefano; D'Avolio, Antonio; Di Perri, Giovanni.
Afiliação
  • Calcagno A; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy andrea.calcagno@unito.it.
  • Dal Conte I; Sexual Health Centre, Department of Prevention, ASL "Città di Torino", Turin, Italy.
  • Cattaneo D; Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
  • Testi R; Sexual Health Centre, Department of Prevention, ASL "Città di Torino", Turin, Italy.
  • Mistrangelo M; Department of Surgical Sciences, University of Turin, Turin, Italy.
  • Gervasoni C; Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
  • de Nicolò A; Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Bonora S; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
  • D'Avolio A; Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Di Perri G; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
Antimicrob Agents Chemother ; 65(1)2021 01 01.
Article em En | MEDLINE | ID: mdl-33106270
ABSTRACT
Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália